Recurrent Salivary Gland Carcinoma Completed Phase 2 Trials for Temsirolimus (DB06287)

IndicationStatusPhase
DBCOND0037143 (Recurrent Salivary Gland Carcinoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01256385Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous TherapyTreatment